<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02310997</url>
  </required_header>
  <id_info>
    <org_study_id>UCL/09/0128</org_study_id>
    <secondary_id>2009-011818-21</secondary_id>
    <nct_id>NCT02310997</nct_id>
  </id_info>
  <brief_title>Myloablative Cord Blood Transplant in Haematological Malignancies (MAC UCBT)</brief_title>
  <acronym>MAC UCBT</acronym>
  <official_title>Transplantation Of Umbilical Cord Blood From Unrelated Donors In Patients With Haematological Diseases Using A Myeloablative Conditioning Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is looking at using umbilical cord blood from unrelated donors after high dose
      chemotherapy. It is for people who have cancer of the bone marrow or lymphatic system
      including leukaemia and lymphoma, or a blood disorder called myelodysplastic syndrome (MDS).

      The trial is for babies over 4 weeks old, children, and adults up to the age of 45.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During treatment for cancers of the bone marrow or lymphatic system, a lot of the stem cells
      are damaged and you may need a bone marrow or stem cell transplant to replace them.

      Stem cells can also be collected from the umbilical cord of newborn babies. Many people
      around the world have donated their baby's umbilical cords which are stored safely.

      There are usually enough cells in one cord to transplant a small child, but there may not be
      enough cells for an older child or adult. Researchers want to see if adults and children can
      safely have stem cells from more than 1 umbilical cord.

      Before a transplant, you have high doses of chemotherapy, sometimes with radiotherapy. This
      intensive conditioning aims to destroy all the cells in your bone marrow, and is called
      myeloablative conditioning.

      The aim of this trial is to see if a transplant using cord blood cells from unrelated donors
      after myeloablative conditioning is safe, and whether it helps people who need a stem cell
      transplant but don't have a stem cell donor.

      You may be able to enter this trial if you:

        -  Have leukaemia, lymphoma or another disorder of the bone marrow and treatment with
           intensive conditioning followed by a stem cell transplant is likely to help you

        -  Do not have a suitable stem cell donor in your family, and your doctors have not been
           able to find a matched unrelated donor

        -  Have satisfactory blood test results

        -  Are between 4 weeks and 45 years old

      You cannot enter this trial if you:

        -  Have a family member who could donate stem cells to you, or you have a matched unrelated
           donor

        -  Can have any other treatment that your doctors think will cure your disease or keep it
           under control for a long time

        -  Have already had a lot of radiotherapy (the trial doctor can advise you about this)

        -  Have already had a bone marrow or stem cell transplant using your own cells

        -  Have chronic myeloid leukaemia that is in chronic phase and is responding to imatinib,
           or is in blast phase and is not responding to treatment Have acute lymphoblastic
           leukaemia that is not responding to treatment or has come back and more than 5% of your
           bone marrow is made up of immature cells (blasts)

        -  Have acute myeloid leukaemia that is not responding to treatment or has come back and
           more than 20% of your bone marrow is made up of immature cells (blasts)

        -  Have a disease that has come back and you are having another type of treatment (salvage
           treatment) but your disease is not responding or is getting worse

        -  Have a blood disorder called myelofibrosis

        -  Have a blood disorder called aplastic anaemia

        -  Have an infection that cannot be controlled with medication

        -  Have either the HIV or HTLV virus

        -  Are pregnant or breastfeeding

      This phase 2 trial aims to recruit 60 people. It will include both adults and children.
      Everybody taking part will have intensive conditioning before having a transplant of stem
      cells from the umbilical cord blood of at least 1 unrelated donor.

      To take part in this trial, the researchers need to be sure that there are 2 lots of cord
      blood cells that would be suitable for you. They will only use cells from 2 cords if there is
      some concern that they won't get enough cells from 1 umbilical cord.

      People aged between 2 and 45 (apart from children under the age of 16 who have acute myeloid
      leukaemia, juvenile myelomonocytic leukaemia (JMML) or MDS) will have conditioning with
      fludarabine, cyclophosphamide and radiotherapy to the whole body (total body irradiation).
      This takes 9 days all together. On the last day, you have the stem cells through a drip into
      a vein.

      Children under 2 years of age (and children up to the age of 16 who have acute myeloid
      leukaemia, JMML or MDS) will have conditioning with busulfan, cyclophosphamide and melphalan.
      They do not have radiotherapy. This conditioning takes 10 days all together. They have the
      stem cells through a drip into a vein on the 11th day.

      The stem cells find their way into your bone marrow where they will start making new blood
      cells.

      You will see the trial team and have some tests before you start treatment. The tests
      include:

        -  Physical examination

        -  Blood tests

        -  Chest X-ray

        -  Lung function tests

        -  Heart trace (ECG)

        -  Heart ultrasound (echocardiogram) or MUGA scan

        -  Bone marrow test When you have your treatment, you will be in hospital for about 4 to 6
           weeks. As you will be at a high risk of infection, you will be in your own room. This is
           called being in isolation. You have another bone marrow test a month after your
           transplant.

      When you go home, you have to go back to the hospital for regular blood tests. This is likely
      to be 2 or 3 times a week to begin with. You may have to go back into hospital for a few days
      at some point.

      After a transplant, you will see the doctors and have blood tests At least once a week for
      the first 3 months At least once a month for the rest of the first year The trial doctors
      will follow your progress closely for at least 2 years.

      The main side effect of the treatment you have just before the transplant is a drop in the
      number of blood cells, causing an increased risk of infection, tiredness and breathing
      problems.

      We have more information about fludarabine, cyclophosphamide, busulfan and melphalan in our
      cancer drugs section.

      It takes longer for blood cells to start growing again after a transplant of cord blood than
      after other types of stem cell transplant. Even when your blood count gets back to normal,
      your immune system may take up to 2 years to recover fully.

      Unfortunately, this treatment can affect your ability to have children (your fertility). Men
      taking part will be offered the option to store sperm (sperm banking) before starting
      treatment. Preserving fertility for women is more complicated and it is important that women
      talk to their doctors about this before starting treatment.

      After any type of bone marrow or stem cell transplant, there is a risk of graft versus host
      disease (GVHD). This happens when the new stem cells attack your body tissue. It mainly
      affects your skin, gut and liver.

      Rarely, the new stem cells fail to start working. This is more common with cord blood
      transplants than with other bone marrow transplants. And even if your transplant is
      successful, there is a risk your disease may come back. Because of these risks, your doctors
      will monitor you very closely after your transplant.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Trial closed early due to poor recruitment
  </why_stopped>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non-relapse mortality at 100 days post transplant</measure>
    <time_frame>100 days post transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival at 1 year</measure>
    <time_frame>1 year post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time course of mixed chimerism established by the donor graft</measure>
    <time_frame>28, 60, 100 days, 6 months, 1 year post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery from neutropenia and cytopenia</measure>
    <time_frame>up to 1 year post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute and chronic GVHD</measure>
    <time_frame>100 Days and 1 year post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of relapse</measure>
    <time_frame>1 year post transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Leukaemia</condition>
  <condition>Lymphoma</condition>
  <condition>Other Haematological Diseases</condition>
  <arm_group>
    <arm_group_label>Fludarabine + Cyclophosphamide + TBI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients aged 2-45 years (excluding AML, JMML and MDS patients aged &lt;16 years) will receive an umbilical cord blood transplant using a myeloablative conditioning regimen comprising:
Fludarabine 25mg/m^2/day day -8 to -6 (total 75mg/m^2) Cyclophosphamide 60mg/kg day -7 and -6 (total 120mg/kg) Total body irradiation 13 - 14.4Gy in 6-8 fractions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Busulfan + Cyclophosphamide + Melphalan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients aged &lt; 2 years and AML, JMML and MDS patients &lt;16 years will receive an umbilical cord blood transplant using a myeloablative conditioning regimen comprising:
Busulfan 3.2mg/kg/day in 2 or 4 doses per day, days -9 to -6 (total 12.8mg/kg). Cyclophosphamide 60mg/kg days -4 and -3 (total 120mg/kg) Melphalan 140mg/m^2 day -2</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Umbilical Cord Blood Transplant</intervention_name>
    <arm_group_label>Fludarabine + Cyclophosphamide + TBI</arm_group_label>
    <arm_group_label>Busulfan + Cyclophosphamide + Melphalan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>Fludarabine + Cyclophosphamide + TBI</arm_group_label>
    <arm_group_label>Busulfan + Cyclophosphamide + Melphalan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total body irradiation</intervention_name>
    <arm_group_label>Fludarabine + Cyclophosphamide + TBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <arm_group_label>Busulfan + Cyclophosphamide + Melphalan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <arm_group_label>Busulfan + Cyclophosphamide + Melphalan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <arm_group_label>Fludarabine + Cyclophosphamide + TBI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be &lt; 45 years of age and â‰¥ 28 days old

          -  Patients with high risk, advanced or poorly responding haematological disease for
             which there is published evidence that haematopoietic stem cell transplantation using
             myeloablative conditioning is likely to be effective

          -  The individual patient's disease status is such that there is no alternative therapy
             likely to achieve cure or provide a significant prolongation of disease-free survival

          -  Left ventricular ejection fraction &gt;45%

          -  Transaminases and bilirubin &lt; twice the upper limit of the normal range

          -  Creatinine clearance &gt; 60mls/min

          -  Comorbidity index of 0 or 1

        Exclusion Criteria:

          -  Patients with a suitably matched sibling donor or 10/10 unrelated volunteer donor
             available within an acceptable time period.

          -  Pregnancy or breastfeeding.

          -  Evidence of HIV or HTLV (I+II) infection or known HIV or HTLV positive serology

          -  Current active serious infection, in particular uncontrolled fungal infection
             -Previous irradiation that precludes the safe administration of an additional dose of
             13- 14.4 Gy of total body irradiation (TBI) in patients aged 2-45 years

          -  Prior autograft

          -  CML in first chronic phase responding to Imatinib or refractory blast crisis

          -  Patients with acute leukaemia in morphological relapse/ persistent disease (defined as
             &gt; 5% blasts in normocellular bone marrow)

          -  Patients with acute myeloid leukaemia with relapse/persistent disease unresponsive to
             re-induction chemotherapy (defined as &gt;20% blasts in normocellular bone marrow)

          -  Malignant disease that is refractory to or progressive on salvage therapy

          -  Myelofibrosis.

          -  Aplastic anaemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rachael Hough</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College London Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University College London Hospital</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>W1T 4TJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Birmingham</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Haematology &amp; Oncology Centre</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St James' University Hospital</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2014</study_first_submitted>
  <study_first_submitted_qc>December 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2014</study_first_posted>
  <last_update_submitted>May 26, 2015</last_update_submitted>
  <last_update_submitted_qc>May 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

